Physician profile
Edwin Lai
NPI 1891824777
$10,823.09
in general payments reported to CMS, 2019-2025
40 companies · $2,165 in 2025
The $2,165 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,643 · 2020: $446 · 2021: $899 · 2022: $1,049 · 2023: $2,078 · 2024: $2,543 · 2025: $2,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,786.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,937.24 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,161.93 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,032.92 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $760.18 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Pfizer INC. | $692.63 | 2019-2025 | |
| Gilead Sciences, INC. | $594.66 | 2019-2025 | |
| Boston Scientific Corporation | $379.12 | 2020-2025 | Apollo Esg Nxt System |
| Regeneron Healthcare Solutions, INC. | $363.91 | 2022-2025 | Dupixent |
| Celgene Corporation | $322.73 | 2021-2024 | Zeposia |
| Genzyme Corporation | $282.59 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $198.20 | 2024-2025 | Vowst, Zenpep |
| Amgen INC. | $150.31 | 2021-2023 | Amjevita, Avsola |
| Intercept Pharmaceuticals, INC. | $140.66 | 2019-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $138.58 | 2024-2025 | Iqirvo, Bylvay |
| Phathom Pharmaceuticals, INC. | $130.14 | 2024-2025 | Voquezna |
Show all 39 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$32,800.65 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Lai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.